WHO essential medicines for children 2011-2019: age-appropriateness of enteral formulations.


Journal

Archives of disease in childhood
ISSN: 1468-2044
Titre abrégé: Arch Dis Child
Pays: England
ID NLM: 0372434

Informations de publication

Date de publication:
04 2022
Historique:
received: 10 02 2021
accepted: 11 08 2021
pubmed: 5 9 2021
medline: 29 4 2022
entrez: 4 9 2021
Statut: ppublish

Résumé

The WHO Essential Medicine List for children (EMLc) is used for promoting access to medicines. The age-appropriateness of enteral (oral and rectal) formulations for children depend on their adaptability/flexibility to allow age-related or weight-related doses to be administered/prescribed and the child's ability to swallow, as appropriate. There is scant information on the age-appropriateness of essential enteral medicines for children. To evaluate the age-appropriateness of enteral essential medicines. Age-appropriateness of all enteral formulations indicated and recommended in the EMLc 3rd to 7th (2011-2019) editions were determined by assessing swallowability and/or dose adaptability for children under 12 years, stratified into five age groups. Enteral formulations in the EMLc were more age-appropriate for older children aged 6-11 years than for younger children. In the 3rd edition, for older children, 77%, n=342, of formulations were age-appropriate. For younger children, age-appropriateness decreased with age group: 34% in those aged 3-5 years, 30% in those aged 1-2 years, 22% among those aged 28 days to 11 months and 15% in those aged 0-27 days. Overall, similar proportions were found for the 7th edition. In contrast, the majority of medicines in the 7th list were age-appropriate in targeted diseases like HIV and tuberculosis. Most recommended enteral essential medicines in EMLc 2011 and 2019 were not age-appropriate for children <6 years. Medicines which are not age-appropriate must be manipulated before administration, leading to potential issues of safety and efficacy. Evaluation of the age-appropriateness of formulations for medicines to be included in EMLc could improve access to better medicines for children in the future.

Identifiants

pubmed: 34479858
pii: archdischild-2021-321831
doi: 10.1136/archdischild-2021-321831
doi:

Substances chimiques

Drugs, Essential 0
Pharmaceutical Preparations 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

317-322

Informations de copyright

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Ebiowei Samuel F Orubu (ESF)

Biomedical Engineering, Boston University, Boston, Massachusetts, USA sforubu@bu.edu.

Jennifer Duncan (J)

Paediatric Medicines Research Unit (PMRU), Alder Hey Children's NHS Foundation Trust, Liverpool, UK.

Catherine Tuleu (C)

School of Pharmacy UCL, London, UK.

Mark A Turner (MA)

Department of Women's and Children's Health, Institute of Life Course and Medical Sciences, University of Liverpool Liverpool Health Partners, Liverpool, UK.
Paediatric Medicines Research Unit (PRMU), Clinical Research Division, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.

Anthony Nunn (A)

Department of Women's and Children's Health, University of Liverpool, Liverpool, UK.
Paediatric Medicines Research Unit (PMRU), Clinical Research Division, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH